RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated ...

Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. <5yrs: not recommended. 5–11yrs: 2 sprays in each nostril 3 times daily. ≥12yrs: 2 sprays in each nostril 3–4 times daily. Epistaxis, dry mouth ...

As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...

Global pharma major Lupin Limited (Lupin) announced the launch of ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (nasal ...

Review the side-effects of Ipratropium Bromide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...